Infinity Pharmaceuticals (INFI) Shares are Up 9.09%

Infinity Pharmaceuticals (INFI) : Traders are bullish on Infinity Pharmaceuticals (INFI) as it has outperformed the S&P 500 by a wide margin of 18.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 9.16%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.09% in the last 1 week, and is up 22.63% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 15.74% and the 50-Day Moving Average is 39.25%. Infinity Pharmaceuticals, Inc. has dropped 71.03% during the last 3-month period . Year-to-Date the stock performance stands at -78.6%.


Infinity Pharmaceuticals (NASDAQ:INFI): stock turned positive on Friday. Though the stock opened at $1.6, the bulls momentum made the stock top out at $1.72 level for the day. The stock recorded a low of $1.55 and closed the trading day at $1.68, in the green by 3.70%. The total traded volume for the day was 1,247,028. The stock had closed at $1.62 in the previous days trading.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.